The interplay between the antiphospholipid syndrome and systemic lupus erythematosus

Antiphospholipid syndrome (APS) was firstly described in systemic lupus erythematosus (SLE), but it was recognized also as a primary APS (PAPS) form. These forms are not always distinguishable, since they show some common clinical/serological manifestations. We actually may deal with: (1) patients initially classified as PAPS gradually developing SLE; (2) patients with SLE and associated APS, whose complications generally affect morbidity and mortality; (3) patients with SLE and positive antiphospholipid antibodies without APS manifestations; the relevant issue in such patients is to provide effective prophylaxis. The close relationship between PAPS and SLE is also supported by: (i) nuclear autoimmunity and (ii) complement activation at least in animal models of APS. Future studies on the genetic background and/or on regulatory suppressive mechanisms may clarify how and why PAPS can evolve into SLE.

[1]  P. Meroni,et al.  Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases) , 2008, Internal and emergency medicine.

[2]  G. Finazzi.  Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No , 2008, Internal and emergency medicine.

[3]  M. Herrmann,et al.  Apoptosis in the pathogenesis of systemic lupus erythematosus , 2008, Lupus.

[4]  A. Tincani,et al.  Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? , 2008, Journal of autoimmunity.

[5]  I. Durieu,et al.  Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. , 2007, Rheumatology.

[6]  S. D'agostini,et al.  General and specific factors associated with severity of cognitive impairment in systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[7]  Y. Shoenfeld.  APS—More Systemic Disease than SLE , 2007, Clinical reviews in allergy & immunology.

[8]  Y. Shoenfeld,et al.  Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus , 2007, Lupus.

[9]  I. Cavazzana,et al.  Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? , 2007, Journal of autoimmunity.

[10]  V. Pascual,et al.  Systemic lupus erythematosus: all roads lead to type I interferons. , 2006, Current opinion in immunology.

[11]  G. Ruiz-Irastorza,et al.  Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus , 2006, Lupus.

[12]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[13]  C. Laskin,et al.  Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts? , 2005, Rheumatic diseases clinics of North America.

[14]  J. Mikdashi,et al.  Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. , 2004, Rheumatology.

[15]  G. Ruiz-Irastorza,et al.  High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. , 2004, Archives of internal medicine.

[16]  G. Hughes.  Hughes syndrome (antiphospholipid syndrome) , 2012 .

[17]  J. Davoust,et al.  Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. , 1998, Arthritis and rheumatism.

[18]  J. Piette,et al.  Exclusion criteria for primary antiphospholipid syndrome. , 1993, The Journal of rheumatology.

[19]  S. Quaglini,et al.  Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.